Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma

被引:0
作者
Fernanda Maria Santos
Jose Flavio Gomes Marin
Marcos Santos Lima
Wellington Fernandes Silva-Junior
Lucas Bassolli O. Alves
Frederico R. Moreira
Rodrigo Dolphini Velasques
Marcelo Junqueira Atanazio
Ana Carolina Arrais Maia
Carlos A. Buchpiguel
Valeria Buccheri
Vanderson Rocha
机构
[1] Faculdade de Medicina,Instituto Do Cancer Do Estado de Sao Paulo (ICESP)
[2] Universidade de Sao Paulo (FMUSP),Nuclear Medicine Medical Investigation Laboratory LIM43
[3] Hospital das Clinicas,Division of Hematology and Cell Therapy
[4] FMUSP (HCFMUSP),Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco
[5] HCFMUSP,Immuno
[6] HCFMUSP,Hematology (LIM
[7] Churchill Hospital,31), Department of Internal Medicine, Division of Hematology
[8] NHS BT,Department of Hematology
[9] Oxford University,undefined
来源
Annals of Hematology | 2024年 / 103卷
关键词
Hodgkin lymphoma; Positron emission tomography; Metabolic tumor volume; Total lesion glycolysis;
D O I
暂无
中图分类号
学科分类号
摘要
Currently, analysis of interim PET (iPET) according to the Deauville score (DS) is the most important predictive factor in Hodgkin lymphoma (HL); however, there is room for improvement in its prognostic power. This study aimed to evaluate the prognostic value of quantitative PET analysis (maximum standard uptake value [SUVmax], total metabolic tumor volume [TMTV] and total lesion glicolysis [TLG]) at baseline (PET0) and iPET in a retrospective cohort of newly diagnosed classical HL. For positive iPET (+ iPET), the reduction of quantitative parameters in relation to PET0 (ΔSUVmax, ΔTMTV and ΔTLG) was calculated. Between 2011 and 2017, 234 patients treated with ABVD were analyzed. Median age was 30 years-old, 59% had advanced stage disease, 57% a bulky mass and 25% a + iPET (DS 4–5). At baseline, high TLG was associated with an increased cumulative incidence of failure (CIF) (p = 0.032) while neither SUVmax, TMTV or TLG were associated with overall survival (OS) or progression-free survival (PFS). In multivariate analysis, only iPET was associated with CIF (p < 0.001). Among ΔSUVmax, ΔTMTV and ΔTLG, only a ΔSUVmax ≥ 68.8 was significant for PFS (HR: 0.31, CI95%: 0.11–0.86, p = 0.024). A subset of patients with improved PFS amongst + iPET was identified by the quantitative (ΔSUVmax ≥ 68.8%) analysis. In this real-world Brazilian cohort, with prevalent high-risk patients, quantitative analysis of PET0 did not demonstrate to be prognostic, while a dynamic approach incorporating the ΔSUVmax to + iPET succeeded in refining a subset with better prognosis. These findings warrant validation in larger series and indicate that not all patients with + iPET might need treatment intensification.
引用
收藏
页码:175 / 183
页数:8
相关论文
共 50 条
[21]   Correlations between baseline18F-FDG PET tumour parameters and circulating DNA in diffuse large B cell lymphoma and Hodgkin lymphoma [J].
Decazes, Pierre ;
Camus, Vincent ;
Bohers, Elodie ;
Viailly, Pierre-Julien ;
Tilly, Herve ;
Ruminy, Philippe ;
Viennot, Mathieu ;
Hapdey, Sebastien ;
Gardin, Isabelle ;
Becker, Stephanie ;
Vera, Pierre ;
Jardin, Fabrice .
EJNMMI RESEARCH, 2020, 10 (01)
[22]   Correlations between baseline 18F-FDG PET tumour parameters and circulating DNA in diffuse large B cell lymphoma and Hodgkin lymphoma [J].
Pierre Decazes ;
Vincent Camus ;
Elodie Bohers ;
Pierre-Julien Viailly ;
Hervé Tilly ;
Philippe Ruminy ;
Mathieu Viennot ;
Sébastien Hapdey ;
Isabelle Gardin ;
Stéphanie Becker ;
Pierre Vera ;
Fabrice Jardin .
EJNMMI Research, 10
[23]   Blood-circulating EV-miRNAs, serum TARC, and quantitative FDG-PET features in classical Hodgkin lymphoma [J].
Drees, Esther E. E. ;
Driessen, Julia ;
Zwezerijnen, Gerben J. C. ;
Verkuijlen, Sandra A. W. M. ;
Eertink, Jakoba J. ;
van Eijndhoven, Monique A. J. ;
Groenewegen, Nils J. ;
Valles-Marti, Andrea ;
de Jong, Daphne ;
Boellaard, Ronald ;
de Vet, Henrica C. W. ;
Pegtel, Dirk M. ;
Zijlstra, Josee M. .
EJHAEM, 2022, 3 (03) :908-912
[24]   Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma [J].
Adams, Hugo J. A. ;
Kwee, Thomas C. .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (06) :491-498
[25]   Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? [J].
Adams, Hugo J. A. ;
Kwee, Thomas C. .
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (01) :122-123
[26]   Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease [J].
Diane Tseng ;
Leelanand P Rachakonda ;
Zheng Su ;
Ranjana Advani ;
Sandra Horning ;
Richard T Hoppe ;
Andrew Quon ;
Edward E Graves ;
Billy W Loo ;
Phuoc T Tran .
Radiation Oncology, 7
[27]   High-risk interim PET negative patients in Hodgkin's lymphoma [J].
Meignan, Michel .
LANCET HAEMATOLOGY, 2016, 3 (10) :E449-E450
[28]   Prognostic values of baseline, interim and end-of therapy 18F-FDG PET/CT in patients with follicular lymphoma [J].
Zhou, Yeye ;
Zhao, Zixuan ;
Li, Jihui ;
Zhang, Bin ;
Sang, Shibiao ;
Wu, Yiwei ;
Deng, Shengming .
CANCER MANAGEMENT AND RESEARCH, 2019, 11 :6871-6885
[29]   Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis [J].
Adams, Hugo J. A. ;
Nievelstein, Rutger A. J. ;
Kwee, Thomas C. .
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (03) :356-366
[30]   Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma [J].
Hutchings, M ;
Mikhaeel, NG ;
Fields, PA ;
Nunan, T ;
Timothy, AR .
ANNALS OF ONCOLOGY, 2005, 16 (07) :1160-1168